HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Expression of EGFR Is Closely Related to Reduced 3-Year Survival Rate in Chinese Female NSCLC.

AbstractBACKGROUND:
Non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung carcinoma cases, which becomes more and more important in the field of lung carcinoma as well as primary lung carcinoma in females.
MATERIAL AND METHODS:
We analyzed the medical history of 62 female NSCLC patients. Immunohistochemistry was used to observe and compare the expression of EGFR. The chi-square test was conducted to analyze associations between EGFR expression and the different variables. The cumulative survival rate was determined by the Kaplan-Meier product-limit method. The prognosis of female patients with NSCLC was examined by using a multivariate Cox proportional hazard regression model.
RESULTS:
The expression proportion of EGFR in Chinese female NSCLC patients was 70.97%, and it was remarkably higher in adenocarcinoma than in squamous cell carcinoma and bronchioloalveolar carcinoma. A positive correlation was observed between EGFR expression and tumor-node metastasis staging or lymph node metastasis. The Cox proportional risk model analysis showed a correlation between postoperative survival time of the patients and pathology of the tumor type and lymph node metastasis.
CONCLUSIONS:
Expression of EGFR was closely related to pathology of the tumor type, tumor-node metastasis staging, and lymph node metastasis, which could be used as a promising indicator of NSCLC in Chinese female patients.
AuthorsGuangyuan Sun, Bing Liu, Jin He, Xuewei Zhao, Bing Li
JournalMedical science monitor : international medical journal of experimental and clinical research (Med Sci Monit) Vol. 21 Pg. 2225-31 (Jul 31 2015) ISSN: 1643-3750 [Electronic] United States
PMID26230859 (Publication Type: Journal Article)
Chemical References
  • ErbB Receptors
Topics
  • Adult
  • Aged
  • Carcinoma, Non-Small-Cell Lung (metabolism, pathology)
  • China
  • ErbB Receptors (metabolism)
  • Female
  • Humans
  • Lung Neoplasms (metabolism, pathology)
  • Middle Aged
  • Proportional Hazards Models
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: